8700 Beverly Boulevard
Davis Building - Room D-1063
118 articles with Capricor
Capricor Therapeutics has placed a voluntary hold on its Phase II clinical trial for a Duchene Muscular Dystrophy treatment on hold after a patient experienced a severe allergic reaction during dosing.
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the MesaCompany will Provide Presentation on Cell and Exosome Therapies and Poster on New Research
Capricor Therapeutics, Inc. will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy, CAP-1002, which is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9, 2018
Capricor Therapeutics will report its second quarter of 2018 financial results and corporate update shortly after the NASDAQ market close on Thursday, August 9. Management will then host a webcast and conference call at 4:30 p.m. ET on August 9.
Capricor Therapeutics announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to study the potential for the company’s next-generation investigational therapeutic platform, designated CAP-2003
Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
The three-day conference brings together scientists, physicians, companies, patients and their families to discuss the latest developments in Duchenne and Becker muscular dystrophy.
Capricor Announces Licensing of Additional Patent Applications From Cedars-Sinai Medical Center for Cellular and Exosome-Based Technologies
New patent applications pave way for capricor to develop potential new therapeutic platforms for duchenne muscular dystrophy and other disorders.
Capricor today announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,828,603, which includes composition of matter claims covering cardiosphere-derived cell exosomes.
This randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial.
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated With Capricor's Investigational Cell Therapy
These findings were reported today by Ronald G. Victor, M.D. at a Late-Breaking Science session of the American Heart Association Scientific Sessions 2017.
Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program
The company reported a net loss of approximately $2.7 million, or $0.12 per share, for the third quarter of 2017, compared to a net loss of approximately $5.3 million, or $0.29 per share, for the third quarter of 2016.
Capricor will report third quarter 2017 financial results shortly after the NASDAQ market close on Wednesday, November 8, 2017.
Capricor Reports Intravenous Administration Of CAP-1002 Shown To Be Effective In Preclinical Models Of Duchenne Muscular Dystrophy
Capricor Presents Positive Six-Month Results In Duchenne Muscular Dystrophy At World Muscle Society International Congress
Capricor Advances Clinical Development Program In Duchenne Muscular Dystrophy With Naming Of Principal Investigator
Capricor Receives Rare Pediatric Disease Designation From FDA For CAP-1002 For Patients With Duchenne Muscular Dystrophy